Brennan Spiegel, MD
Gastroenterology · Los Angeles, CANPI 1184644189
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $127,507 of the $140,967 with a category attached, or 90.5%. 18 manufacturers reported payments, led by Ironwood Pharmaceuticals, Inc at 44.6% of the total. Reporting peaked in 2021 at $39,653 and has fallen 95.0% since, to $1,992 in 2025. Among gastroenterology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 107 payments — averaging $1317.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironwood Pharmaceuticals, Inc$63K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$15K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- AbbVie$12K
- Intercept Pharmaceuticals, Inc.$9K
- Eli Lilly$7K
- plus $22K from 12 others
Across 23 payments — averaging $32,677 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$547K
- Alnylam Pharmaceuticals Inc.$102K
- Bausch Health US, LLC$101K
- Novartis$3K
What the payments were for
- Consulting fees$127,50790%
- Speaking & faculty fees$3,8193%
- Travel & lodging$4,5003%
- Food & beverage$5,1414%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironwood Pharmaceuticals, Inc | 7 | $62,900 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $14,835 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $12,941 |
| AbbVie(2 entities) | 7 | $11,884 |
| Intercept Pharmaceuticals, Inc. | 2 | $9,335 |
| Eli Lilly | 8 | $7,387 |
| Alnylam Pharmaceuticals Inc. | 6 | $5,598 |
| Ferring Pharmaceuticals Inc. | 3 | $5,390 |
| Biogen | 1 | $3,565 |
| Ardelyx, Inc. | 17 | $3,297 |
| Exact Sciences | 2 | $1,893 |
| Pfizer | 1 | $924 |
| Phathom Pharmaceuticals, Inc. | 3 | $391 |
| Vibrant Gastro, Inc. | 2 | $275 |
| Mallinckrodt Hospital Products Inc. | 2 | $213 |
| Sanofi | 1 | $97 |
| Redhill Biopharma Inc. | 1 | $22 |
| Mahana Therapeutics, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$140,967 in reported general payments places this provider in the 95th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Los Angeles
- Bennett RothLos Angeles$2.8M
- Sammy SaabLos Angeles$1.9M
- Sadeea AbbasiLos Angeles$556K
- Gil MelmedLos Angeles$467K
- Venkataraman MuthusamyLos Angeles$297K
- Caroline HwangLos Angeles$279K
- Adarsh ThakerLos Angeles$241K
- Andres YarurLos Angeles$218K
- Joseph PisegnaLos Angeles$210K
- Steven-Huy HanLos Angeles$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.